Standout Papers
Citation Impact
Citing Papers
Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
2005
Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector
2006 StandoutNobel
Industrial biocatalysis today and tomorrow
2001 StandoutNature
Molecular Cloning and Characterization of an Aquaporin cDNA from Salivary, Lacrimal, and Respiratory Tissues
1995 StandoutNobel
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience)
2000
EGFR Antagonists in Cancer Treatment
2008 Standout
Current clinical outcomes demand new treatment options for SCCHN
2005
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Hemoglobin disorders and endothelial cell interactions
2009
Testicular Germ-Cell Cancer
1997 Standout
Final report of RTOG 9610, a multi‐institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck
2007
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
1992
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Ovarian cancer
2014 Standout
Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
2008 Standout
Towards Engineering Hormone-Binding Globulins as Drug Delivery Agents
2014
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Head and neck cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Interferons in the pathogenesis and treatment of human immunodeficiency virus infection
1994
Essential thrombocythemia
2003
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Esophageal Cancer
2003 Standout
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
1993
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck
1998
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma
2014
LONG-TERM SURVIVORS OF CHILDHOOD CANCER
1997
Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?
2005
WebEAV: Automatic Metadata-driven Generation of Web Interfaces to Entity-Attribute-Value Databases
2000
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
1995
Nasopharyngeal carcinoma
2015 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: A gynecologic oncology group study
2005
Sickle-cell disease
2010 Standout
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer
2000
The Simultaneous Generation of Superoxide and Nitric Oxide Can Initiate Lipid Peroxidation in Human Low Density Lipoprotein
1992
Head and Neck Cancer
1993 Standout
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
1993
End points for new agents in induction chemotherapy for locally advanced head and neck cancers
2002
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
2015
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS
2005 StandoutNobel
Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts
1995
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
1995
Combinatorial biocatalysis: a natural approach to drug discovery
1998
Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
2007
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Prognostic factors and long‐term survivorship in patients with recurrent or metastatic carcinoma of the head and neck
2004
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
Anemia of Chronic Disease
2005 Standout
Head and Neck Cancer
2001 Standout
Increased F 2 Isoprostanes in the Acute Chest Syndrome of Sickle Cell Disease as a Marker of Oxidative Stress
2001
5 Amidines and Guanidines in Medicinal Chemistry
1993
Studies on amino acid control of cellular function
1974 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Emerging DNA topoisomerase inhibitors as anticancer drugs
2004
Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer
2001
Natural Product Synthesis Using Multicomponent Reaction Strategies
2009 Standout
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Head and Neck Cancer
2020 Standout
Isolation and characterization of proteoglycans from chick limb bud chondrocytes grown in vitro.
1976
Kinetics of Early Changes in Phosphate and Uridine Transport and Cyclic AMP Levels Stimulated by Serum in Density-Inhibited 3T3 Cells
1974 StandoutNobel
Additions to Metal-Activated Organonitriles
2002 Standout
Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels
1982 Standout
The Expanding Role of Systemic Therapy in Head and Neck Cancer
2004
Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group
2005
Surfing the p53 network
2000 StandoutNature
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
2006
Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data
2000 Standout
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Requirement for protein synthesis in the regulation of protein breakdown in cultured hepatoma cells
1975 StandoutNobel
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Control over overall shape and size in de novo designed proteins
2015 StandoutNobel
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS
2005 StandoutNobel
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2003
Pleiotypic Control by Adenosine 3′:5′-Cyclic Monophosphate: A Model for Growth Control in Animal Cells
1973
Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2006
Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911
2007
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Chronic myelogenous leukemia: a concise update
1993
Control of Initiation of Protein Synthesis in Human Cells
1973
A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma
1996
Works of Lee Schacter being referenced
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
1992
A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days*
1995
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
1996
Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors
1996
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.
1991
Megestrol acetate: clinical experience
1989
Phase II study of elsamitrucin in non-small cell lung cancer
1994
Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer.
1995
Anagrelide: A New Drug for Treating Thrombocytosis
1988
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
1992
Managing Attribute-Value Clinical Trials Data Using the ACT/DB Client-Server Database System
1998
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
1996
Measurement of free radical oxygen generation by cyrochrome c reduction requirement for cytochrome c oxidase blockade
1985
Etoposide phosphate: what, why, where, and how?
1996
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.
2009
The pleiotypic response in mammalian cells: Search for an intracellular mediator
1972 StandoutNobel
Drug discovery and development in the pharmaceutical industry.
1992
Effect of conditioned media on differentiation in mass cultures of chick limb bud cells
1970
Overview of hormonal therapy in advanced breast cancer.
1990
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial
2006
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial
2006
Altered amount and activity of superoxide dismutase in sickle cell anemia
1988
Fatal radiation hepatitis: A case report and review of the literature
1986